Evotec Reports Results of the Annual General Meeting 2026
Evotec (NASDAQ:EVO) reported results of its Annual General Meeting 2026 held in Hamburg, Germany.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Evotec (NASDAQ:EVO) reported results of its Annual General Meeting 2026 held in Hamburg, Germany.
All agenda items were adopted with the required majority. Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board, and re-elected Dr. Duncan McHale and Wesley Wheeler. Weinand was appointed Chairman. 43.10% of registered share capital was represented.
Positive
- All AGM 2026 agenda items adopted with required majority
- Two new Supervisory Board members elected by shareholders
- Supervisory Board Chairman role transitioned to Dieter Weinand
- Two existing Supervisory Board members successfully re-elected
- 43.10% of registered share capital represented at AGM
Negative
- None.
Details
News Market Reaction – EVO
On Jun 11, the day this news came out, EVO closed 4.21% above the previous close.
Data tracked by StockTitan Argus for the Jun 11 session.
Key Figures
- Share capital represented
- 43.10%
- 2026 Annual General Meeting
Historical Context
-
Appointment of EVP to lead global in silico and AI initiatives.
-
Placement of €116.1M senior unsecured convertible bonds due 2033.
-
Nomination of first small-molecule preclinical development candidate with Almirall.
-
Two Gates Foundation grants totaling $9.9M for TB drug discovery and development.
-
Nomination of Dr. Hofmann and cooperation agreement with key shareholder MAK Capital.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
11.06.2026 / 15:30 CET/CEST
The issuer is solely responsible for the content of this announcement.
- All agenda items adopted
- Dieter Weinand and Dr. Wolfgang Hofmann newly elected to the Supervisory Board
- Dieter Weinand appointed Chairman of the Supervisory Board
- Dr. Duncan McHale and Wesley Wheeler re‑elected to the Supervisory Board
All agenda items put to vote were adopted by the Company's shareholders with the required majority.
Shareholders elected Dieter Weinand and Dr. Wolfgang Hofmann to the Supervisory Board. Following the Annual General Meeting, the Supervisory Board appointed Dieter Weinand as its Chairman, succeeding Prof. Dr. Iris Löw-Friedrich. In addition, shareholders approved the re-election of Dr. Duncan McHale and Wesley Wheeler to the Supervisory Board.
Overall,
Further information on the Company's Annual General Meeting, including the voting results on all agenda items, will be made available shortly on Evotec's website.
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure — faster, smarter, and with greater precision. Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling. With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility. Through Just – Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability. With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology. Evotec's global team of more than 4,500 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec.
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
Investor Relations and Media Contact
Dr. Sarah Fakih
EVP Head of Global Communications & Investor Relations
Sarah.Fakih@evotec.com
View original content:https://www.prnewswire.com/news-releases/evotec-reports-results-of-the-annual-general-meeting-2026-302798303.html
SOURCE Evotec SE
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.